| 영문 | Dilatation and Curettage(D & C) | 한글 | 자궁긁어냄술, 자궁목확장 |
|---|---|---|---|
| 설명 | 자궁이란 태아가 수태되어서 분만전까지 발육하고 성장하는 공간이다. 자궁속에 병변이 있어 임신이 계속될 수 없거나 아니면 다른 이유로 임신되어 있는 태아를 제거하고자 할 경우에 사용되는 방법이다. 여기서 긁어내기 위하여는 우선 자궁의 입구에 해당하는 자궁목을 확장시켜야 한다. 여기에는 급속히 확장을 시도하는 법과 서서히 확장을 시도하는 2가지 방법이 있다. 자궁목을 급속히 확장할 때는 헤가르 목관확장기(Hegar's dilatator)를 사용한다. 이것은 작은 금속막대로 작은 크기부터 큰 크기까지 다양한 크기가 있어서 우선 작은 막대로 시작하여 점점 큰 크기의 막대를 자궁목에 넣어서 자궁목을 확장시킨다. 서서히 확장시킬 때는 Laminaria tent를 목관에 삽입하는 방법을 사용한다. Laminaria tent란 해초로 만든 작은 막대로 수분을 흡수하면 점점 늘어나는 성질이 있다. 이것을 자궁의 목에 넣으면 이것이 수분을 흡수하여 늘어나므로 천천히 자궁의 목이 늘어난다. 자궁목이 충분히 늘어나면 그 속으로 끝이 숟가락처럼 생긴 기구를 넣어서 자궁속의 병변이나 임신된 태아를 긁어내는데 여기에 사용되는 숟가락처럼 생긴 기구를 큐렛이라고 한다. 초기 임신중절 즉 유산과 같은 임신과 관련된 경우뿐만 아니라, 비임신 자궁의 자궁내막조직의 채취 및 제거를 위해서도 행해지는 수기이다. 이는 원칙적으로 마취하에 실시되는 것으로 자궁목관을 확장하고 기구로 자궁 내용물을 제거하고 큐렛으로 자궁내벽을 깨끗이 한다. 자궁천공이나 자궁목의 파열 등의 위험이 따르며, 수술후 감염 또는 출혈 등에 대한 주의가 필요하다. |
||
| FCS | faciocutaneoskeletal syndrome; fecal containment system; feedback control system; fetal calf serum; ... |
|---|---|
| MCL | maximum containment laboratory; medial collateral ligament; midclavicular line; midcostal line; mini... |
| COMPASS | Computerized Online Medicaid Pharmaceutical Analysis and Surveillance System |
| HASP | Hospital Admissions and Surveillance Program |
| ISCP | infection surveillance and control program; International Society of Comparative Pathology |
| AHCCCS | Arizona Health Care Cost Containment System |
|---|---|
| ABLES | Adult Blood Lead Epidemiology and Surveillance program |
| NREVSS | National Respiratory and Enteric Virus Surveillance System |
| SEER | Surveillance Epidemiology and End Results |
| SEER | Surveillance, Epidemiology and End Results Program |
acute angle
| cancer, colon: screening and surveillance | Colon cancer is both preventable and curable. It is preventable by removing precancerous colon polyps. It is curable if early cancer is surgically removed before cancer spread to other parts of the body. Therefore, if screening and surveillance programs were practiced universally, there would be a major reduction in the incidence and mortality of colon cancer. (12 Dec 1998) |
|---|---|
| biological containment | <molecular biology> Refers to any number of methods to contain genetically engineered organisms by creating biochemical barriers to prevent them from growing outside the laboratory. In the case of bacteria and yeasts, genes in the organisms may be altered so that they need to have a supply of a nutrient that is normally found only in the laboratory. (21 Mar 1998) |
| physical containment | <cell culture> Creation of physical barriers to keep genetically engineered organisms inside the laboratory. (31 Dec 1997) |
| plasma containment | <physics> In physics experiments or nuclear fusion experiments, operation is intended to prevent, in an effective and sufficiently prolonged manner, the particles of a plasma from striking the walls of the container in which this plasma is produced. Plasma confinement is a fundamental requirement for obtaining net energy from a fusion plasma. The reason is that scattering (hence diffusion) is at least an order of magnitude more probable than fusion reactions. Hence, without confinement, the plasma fuel would disperse before enough fusion reactions could take place. (31 Dec 1997) |
| containment | The concept of regional or global eradication of communicable disease, proposed by Fred Lowe Soper (1893-1977) in 1949 for the eradication of smallpox. (05 Mar 2000) |
| containment of biohazards | Provision of physical and biological barriers to the dissemination of potentially hazardous biologically active agents (bacteria, viruses, recombinant DNA, etc.). Physical containment involves the use of special equipment, facilities, and procedures to prevent the escape of the agent. Biological containment includes use of immune personnel and the selection of agents and hosts that will minimise the risk should the agent escape the containment facility. (12 Dec 1998) |
| containment vessel | <radiobiology> Gas-tight shell or other enclosure around a fusion (or fission) reactor, to prevent accidental leakage of radioactive contents. (09 Oct 1997) |
| population surveillance | <epidemiology> Ongoing scrutiny of a population (general population, study population, target population, etc.), generally using methods distinguished by their practicability, uniformity, and frequently their rapidity, rather than by complete accuracy. (12 Dec 1998) |
| post-marketing surveillance | Procedure implemented after a drug has been licensed for public use, designed to provide information on use and on occurrence of side effects, adverse effects, etc. (05 Mar 2000) |
| product surveillance, postmarketing | Surveillance of drugs, devices, appliances, etc., for efficacy or adverse effects, after they have been released for general sale. (12 Dec 1998) |
| sentinel surveillance | Monitoring of rate of occurrence of specific conditions to assess the stability or change in health levels of a population. It is also the study of disease rates in a specific cohort, geographic area, population subgroup, etc. To estimate trends in larger population. (12 Dec 1998) |
| surveillance | Oversight; watch; inspection; supervision. "That sort of surveillance of which . . . The young have accused the old." (Sir W. Scott) Origin: F, fr. Surveiller to watch over; sur over + veiller to watch, L. Vigilare. See Sur-, and Vigil. Source: Websters Dictionary (01 Mar 1998) |
| immune surveillance | <immunology> The hypothesis that lymphocyte traffic ensures that all or nearly all parts of the vertebrate body are surveyed by visiting lymphocytes in order to detect any altered self material, for example mutant cells. (18 Nov 1997) |
| immunological surveillance | <immunology> The hypothesis that lymphocyte traffic ensures that all or nearly all parts of the vertebrate body are surveyed by visiting lymphocytes in order to detect any altered self material, for example mutant cells. (18 Nov 1997) |
| immunologic surveillance | The theory that T-cells monitor cell surfaces and detect structural changes in the plasma membrane and/or surface antigens of virally or neoplastically transformed cells. (12 Dec 1998) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|